Description

Health Canada carried out a safety review to investigate the potential risk of developing an abnormal heart rhythm (QT interval prolongation) with the use of over-the-counter (OTC) drug products containing loratadine. This safety review was triggered by a publication, in the World Health Organization (WHO) Pharmaceuticals NewsletterFootnote1, describing cases of an abnormal heart rhythm (QT interval prolongation) possibly associated with the use of loratadine and desloratadine.

Resources

Name	Format	Description	Link
Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation)	HTML		https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-loratadine-abnormal-heart-rhythm-interval-prolongation.html
Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation)	HTML		https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-loratadine-abnormal-heart-rhythm-interval-prolongation.html
Summary Safety Review - Loratadine - Abnormal heart rhythm (QT interval prolongation)	HTML		https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medeffet-canada/examens-innocuite/resume-examen-innocuite-loratadine-anomalie-rythme-cardiaque-allongement.html

Tags

Topics

Categories